Interní Med. 2012; 14(10): 386-388
The Role of Candesartan in the Therapy and Prevention of Cardiovasular Diseases
- Koronární jednotka Interního oddělení, Oblastní nemocnice Kladno
In the past years there has been a big progress on the field of prevention and therapy of arterial hypertension a heart failure, which are the
most important risk factors of morbidity and mortality in the developed countries. As the understanding of the pathophysiology and
clinical presentation of these diseases gets deeper, new approaches in the prevention and therapy have been developed. Very successful
group of medication are the angiotensin-receptor blockers (ARB). Especially candesartan has reached great results with maintained
excellent safety profile. For this reason candesartan nowadays belongs to the standard therapy of hypertension and heart failure.
Keywords: arterial hypertension, heart failure, candesartan, CHARM
Published: November 1, 2012 Show citation
References
- Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens. 1997 Sep; 11(Suppl 2): S19-25.
- Van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens. 1997 Sep; 11(Suppl 2): S27-28.
Go to PubMed... - Bönner G, Fuchs W. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. Curr Med Res Opin. 2005 Jun; 21(6): 935-940.
Go to original source... Go to PubMed... - Morsing P. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol. 1999 Jan; 10 (Suppl 11): S248-254. Go to PubMed...
- Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens. 1997 Sep; 11 (Suppl 2): S49-53. Go to PubMed...
- Degl'Innocenti A, Elmfeldt D, Hansson L, Breteler M, James O, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A, Wiklund I. Cognitive function and health-related quality of life in elderly patients with hypertension-baseline data from the study on cognition and prognosis in the elderly (SCOPE). Blood Press. 2002; 11(3): 157-165. Go to original source... Go to PubMed...
- Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. J Hypertens. 2011 Jul; 29(7): 1457-1462. Go to original source... Go to PubMed...
- Belcher G, Hübner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens. 1997 Sep; 11(Suppl 2): S85-89. Go to PubMed...
- Kjeldsen SE, St?lhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens. 2010 Apr; 24(4): 263-773. Epub 2009 Nov 5. Go to original source... Go to PubMed...
- McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B; CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003 Jun; 5(3): 261-270. Go to original source... Go to PubMed...
- Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004 Oct 26; 110(17): 2618-2626. Epub 2004 Oct 18. Go to original source... Go to PubMed...
- Slíva J. Candesartan v léčbě kardiovaskulárních onemocnění. Farmakoterapie. 1/2012; 8: 118-122.